Review article: vascular effects of PPARs in the context of NASH

Role of liver sinusoidal endothelial cells in liver diseases

(2021) Jordi Gracia-Sancho et al.   Nature Reviews Gastroenterology & Hepatology

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial

(2021) Samer Gawrieh et al.   HEPATOLOGY

Role of extracellular vesicles in liver diseases and their therapeutic potential

(2021) Enis Kostallari et al.   ADVANCED DRUG DELIVERY REVIEWS

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

(2021) Atsushi Nakajima et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

(2021) Alessandro Mantovani et al.   Lancet Gastroenterology & Hepatology

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer

(2021) Albert Gibert-Ramos et al.   Cancers

Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease

(2020) Jacqueline B. Henson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Metabolic inflammation - a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)?

(2020) Nadine Gehrke et al.   GASTROENTEROLOGY

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

(2020) Giovanni Targher et al.   GUT

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

(2020) Sander Lefere et al.   JOURNAL OF HEPATOLOGY

Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis

(2020) Haiou Li et al.   Frontiers in Immunology

PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction

(2020) Xiaozhe Yin et al.   Cell Reports

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

(2020) Zoe Boyer-Diaz et al.   JOURNAL OF HEPATOLOGY

The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art

(2019) Ruben Esse et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary

(2019) Donna K. Arnett et al.   CIRCULATION

Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue

(2019) Samuel J. Daniels et al.   BIOMEDICINE & PHARMACOTHERAPY

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

(2019) Mohsen Malehmir et al.   NATURE MEDICINE

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

(2019) Upendra Kaul et al.   Cardiovascular Diabetology

Regulation of hepatokine gene expression in response to fasting and feeding: Influence of PPAR-α and insulin-dependent signalling in hepatocytes

(2019) S. Smati et al.   DIABETES & METABOLISM

The PPAR–microbiota–metabolic organ trilogy to fine-tune physiology

(2019) Hui Yun Penny Oh et al.   FASEB JOURNAL

Liver and insulin resistance: New wine in old bottle!!!

(2019) Bhoomika M. Patel et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study

(2019) Francesco Baratta et al.   Clinical Gastroenterology and Hepatology

Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension

(2018) Hung-Cheng Tsai et al.   AMERICAN JOURNAL OF PATHOLOGY

A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer?

(2018) Xu Cao et al.   ANTIOXIDANTS & REDOX SIGNALING

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone

(2018) Lawrence H. Young et al.   CIRCULATION

Circulating Sulfatide, A Novel Biomarker for ST-Segment Elevation Myocardial Infarction

(2018) Gang Li et al.   Journal of Atherosclerosis and Thrombosis

Is pulmonary vascular disease reversible with PPAR ɣ agonists?

(2018) Peter Afdal et al.   MICROCIRCULATION

Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases

(2018) Maria Angela Incalza et al.   VASCULAR PHARMACOLOGY

Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

(2018) Zobair Younossi et al.   HEPATOLOGY

Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction

(2018) Ting-Ting Tang et al.   Theranostics

Peroxisome proliferator-activated receptor α attenuates high-cholesterol diet-induced toxicity and pro-thrombotic effects in mice

(2018) Yu Lu et al.   ARCHIVES OF TOXICOLOGY

Hepatic microcirculation and mechanisms of portal hypertension

(2018) Jordi Gracia-Sancho et al.   Nature Reviews Gastroenterology & Hepatology

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets

(2017) Gyongyi Szabo et al.   Nature Reviews Gastroenterology & Hepatology

Association of PPAR Alpha Intron 7 G/C, PPAR Gamma 2 Pro12Ala, and C161T Polymorphisms with Serum Fetuin-A Concentrations

(2017) Bernadett Márkus et al.   PPAR Research

Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis

(2017) Shaoli Zhou et al.   Scientific Reports

Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis

(2017) Hye Jin Yoo et al.   PLoS One

Aspirin use is associated with lower indices of liver fibrosis among adults in the United States

(2016) Z. Gordon Jiang et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

(2016) Alexandra Montagner et al.   GUT

Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysis

(2016) Yining Dai et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux

(2016) Varman T. Samuel et al.   JOURNAL OF CLINICAL INVESTIGATION

Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications

(2016) Sven M. Francque et al.   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Preserved hemostatic status in patients with non-alcoholic fatty liver disease

(2016) Wilma Potze et al.   JOURNAL OF HEPATOLOGY

Immunology in the liver — from homeostasis to disease

(2016) Felix Heymann et al.   Nature Reviews Gastroenterology & Hepatology

Association of homoarginine and methylarginines with liver dysfunction and mortality in chronic liver disease

(2015) Stefan Pilz et al.   AMINO ACIDS

Relationship between carotid artery atherosclerosis and sulfatide in hypertensive patients

(2015) G. Li et al.   GENETICS AND MOLECULAR RESEARCH

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

(2015) Sven Francque et al.   JOURNAL OF HEPATOLOGY

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

(2015) Bing Sun et al.   Lipids in Health and Disease

LECT2 induces atherosclerotic inflammatory reaction via CD209 receptor-mediated JNK phosphorylation in human endothelial cells

(2015) Hwan-Jin Hwang et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Transcriptomic signatures of peroxisome proliferator-activated receptor α (PPARα) in different mouse liver models identify novel aspects of its biology

(2015) Ewa Szalowska et al.   BMC GENOMICS

Association between serum sulfatide and carotid intima media thickness in patients with familial hypercholesterolemia

(2014) Gang Li et al.   GLYCOCONJUGATE JOURNAL

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

(2014) Michal Pawlak et al.   HEPATOLOGY

Procoagulant imbalance in patients with non-alcoholic fatty liver disease

(2014) Armando Tripodi et al.   JOURNAL OF HEPATOLOGY

Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats

(2014) Philipp Schwabl et al.   JOURNAL OF HEPATOLOGY

The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us?

(2014) Ann Rumley et al.   THROMBOSIS AND HAEMOSTASIS

Peroxisome Proliferator-Activated Receptor-γ Mutations Responsible for Lipodystrophy With Severe Hypertension Activate the Cellular Renin–Angiotensin System

(2013) Martine Auclair et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Nonalcoholic fatty liver disease and serum lipoproteins: The Multi-Ethnic Study of Atherosclerosis

(2013) Andrew Paul DeFilippis et al.   ATHEROSCLEROSIS

Activation of PPAR  Ameliorates Hepatic Insulin Resistance and Steatosis in High Fructose-Fed Mice Despite Increased Endoplasmic Reticulum Stress

(2013) S. M. H. Chan et al.   DIABETES

Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

(2013) B. Cariou et al.   DIABETES CARE

Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

(2013) An Verrijken et al.   HEPATOLOGY

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

Hepatic Methionine Homeostasis Is Conserved in C57BL/6N Mice on High-Fat Diet Despite Major Changes in Hepatic One-Carbon Metabolism

(2013) Christoph Dahlhoff et al.   PLoS One

Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease

(2012) Chiara Marchesi et al.   CARDIOVASCULAR RESEARCH

Suppression of ERR targets by a PPARα/Sirt1 complex in the failing heart

(2012) Shin-ichi Oka et al.   CELL CYCLE

Cullin-3 Regulates Vascular Smooth Muscle Function and Arterial Blood Pressure via PPARγ and RhoA/Rho-Kinase

(2012) Christopher J. Pelham et al.   Cell Metabolism

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

(2012) G. Musso et al.   DIABETOLOGIA

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

(2012) Erica Villa et al.   GASTROENTEROLOGY

PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats

(2012) Aina Rodríguez-Vilarrupla et al.   JOURNAL OF HEPATOLOGY

Hepatic Cerebroside Sulfotransferase Is Induced by PPARα Activation in Mice

(2012) Takefumi Kimura et al.   PPAR Research

PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH

(2011) Morgane Baron et al.   ATHEROSCLEROSIS

The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update

(2011) Hanrui Zhang et al.   BASIC RESEARCH IN CARDIOLOGY

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

(2011) Harold E. Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients

(2011) Esther Zimmermann et al.   JOURNAL OF HEPATOLOGY

PPARα Expression Protects Male Mice from High Fat–Induced Nonalcoholic Fatty Liver

(2011) Mohamed A. Abdelmegeed et al.   JOURNAL OF NUTRITION

Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice

(2011) Yingchang Lu et al.   PHYSIOLOGICAL GENOMICS

Pioglitazone in the treatment of NASH: the role of adiponectin

(2010) A. Gastaldelli et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

PPARα deficiency augments a ketogenic diet-induced circadian PAI-1 expression possibly through PPARγ activation in the liver

(2010) Katsutaka Oishi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Fenofibrate Treatment Enhances Antioxidant Status and Attenuates Endothelial Dysfunction in Streptozotocin-Induced Diabetic Rats

(2010) Murat Olukman et al.   Experimental Diabetes Research

PPARs as therapeutic targets in cardiovascular disease

(2010) Marc van Bilsen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation

(2010) Sihao Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

(2010) Renata Belfort et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease

(2010) Anna Kotronen et al.   LIVER INTERNATIONAL

Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease

(2009) Silvia Sookoian et al.   ATHEROSCLEROSIS

Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity

(2009) Rinke Stienstra et al.   HEPATOLOGY

SUMOylation of Human Peroxisome Proliferator-activated Receptor α Inhibits Its Trans-activity through the Recruitment of the Nuclear Corepressor NCoR

(2009) Benoit Pourcet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulationin vitroandin vivoin a rat model

(2009) Sven Francque et al.   LIVER INTERNATIONAL

Proteomic profiling of human plasma exosomes identifies PPARγ as an exosome-associated protein

(2008) Christopher Looze et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Overexpression of human truncated peroxisome proliferator-activated receptor   induces apoptosis in HL-1 cardiomyocytes

(2008) J. Beaumont et al.   CARDIOVASCULAR RESEARCH

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus

(2008) Katsuhito Mori et al.   METABOLISM-CLINICAL AND EXPERIMENTAL